BioSpace News Archive

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in Citi’s 16th Annual BioPharma Virtual Conference 2021 investor conference.

TriSalus Life Sciences®, an emerging immuno-oncology company committed to transforming outcomes for patients with liver and pancreatic tumors, today announced its first patient enrolled in the Pressure Enabled Regional Immuno-Oncology (PERIO)-01 clinical study evaluating the administration of SD-101, an investigational toll-like receptor 9 (TLR9) agonist, in adults with metastatic uveal melanoma.

Systems Oncology LLC, a privately held biopharmaceutical company developing a new class of multi-modal RNA therapeutics, announced today that the management team will be presenting and participating at the following upcoming conferences.

Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB:ACOGF)(“Alpha Cognition”, or the “Company”), is pleased to announce the U.S. Food and Drug Administration (“FDA”) has accepted its Investigational New Drug (IND) application for lead candidate, ALPHA-1062, to proceed with the pivotal clinical phase (the “Pivotal”) of the development program.

Arcturus Therapeutics Holdings Inc., a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, announced that the Company will participate in upcoming investor and scientific conferences.

CEVEC Pharmaceuticals GmbH announced the signing of an agreement with UCB S.A. on the evaluation and use of CEVEC’s proprietary ELEVECTA Technology for the research, development, and manufacturing of Adeno-Associated Virus vectors for gene therapy applications.

Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced the appointment of Marcin Kortylewski, Ph.D. as Senior Scientific Advisor of Duet Therapeutics.

Illumina, Inc. (NASDAQ: ILMN) and Merck (known as MSD outside the United States and Canada) today announced a partnership to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency (HRD)

Aditxt, Inc. today announced it has closed on a registered direct offering for $11 million announced on August 26, 2021 and funded a bridge loan to its acquisition target, satisfying a key term of the Letter of Intent (LOI).

BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, will showcase three scientific posters regarding BELBUCA® (buprenorphine buccal film), CIII at the PAINWeek 2021 Conference taking place September 7 – 11, 2021 at The Cosmopolitan of Las Vegas.